featured
Systemic Treatment for Patient With Progressing mCRPC
- Written by
-
Pedro
C.
Barata
MD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Gregory Lewis
4 - pembrolizumab In prostate cancer, CDK12 mutations occur in 5%−7% of patients with mCRPC, and most are biallelic inactivations. CDK12-altered/mutated prostate cancer is an aggressive subtype with poor responses and outcomes to hormonal, taxane, and PARP inhibitor therapies. A proportion of these patients may respond favorably to PD-1 inhibitors, which implicates CDK12 deficiency in immunotherapy sensitivity.
Juan Artigas
He should be treated with cabazitaxel and pembrolizumab. CDK12 does not respond to PARP inhibitors.
Bahram Mofid
He should be treared with pembrolizumab